TATAA Biocenter Announces the Opening of New GLP Compliant Laboratory in Gothenburg, Sweden
TATAA Biocenter, an industry-leading nucleic acid analysis services provider, is excited to announce the opening of a Good Laboratory Practice (GLP) compliant facility in Gothenburg, Sweden. The new facility, which is set to open on December 3rd, 2021, will specialize in quality control (QC) analytics to better support the needs of gene and cell therapeutics.
TATAA Biocenter, an industry-leading nucleic acid analysis services provider, is excited to announce the opening of a Good Laboratory Practice (GLP) compliant facility in Gothenburg, Sweden. The new facility, which is set to open on December 3rd, 2021, will specialize in quality control (QC) analytics to better support the needs of gene and cell therapeutics.
By specializing in QC analytics, TATAA is hoping to address unmet needs within nucleic acid-based drugs, especially within gene and cell therapies, where impurities in the product could pose significant risk and danger to patients’ lives. Unlike traditional contract research organizations and established laboratories, TATAA differentiates itself by offering new methods that meet the sensitivity requirements necessary for robust molecular analyses for these projects. TATAA’s new 2,000-square-meter facility is customized to minimize contamination and optimize their laboratory workflow.
The new GLP facility complements TATAA’s existing ISO 17025:2018 accreditation. TATAA will continue to design and validate custom assays for their customers and are excited to enhance their existing services by tracing samples throughout the analytical process. TATAA also provides routine product testing, courses, and contamination-prevention consulting.
TATAA Biocenter is leading provider of molecular services to the Advanced Therapies and Medical products (ATMP) industry in Europe and the Cell and Gene Therapy in the United States. With ISO 17025 accreditation and Good Laboratory and Clinical Practices (GLP/GCP) TATAA is perfectly positioned to support the pharmaceutical industry with biomarker profiling including genomics, transcriptomics, proteomics and microbiomics with traditional qPCR, dPCR and NGS methods as well as proprietary methods.
